Flexion Therapeutics Inc (FLXN)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

10 MALL ROAD BURLINGTON, MA 01803

Flexion Therapeutics Inc discovers and develops therapeutics for musculoskeletal disorders. The company offers pharmaceuticals and developed delivery systems for the treatment of refractory end-stage pain.

Data based on most recent fiscal year report
Market Cap921.607 Million Shares Outstanding37.54 Million Avg Volume1.329 Million
1-Yr BETA vs S&P TR Current Ratio13.02 Quick Ratio12.96
View SEC Filings from FLXN instead.
Q1 2019 All Institutions Hedge Funds 1
To trade FLXN now:
Filers who had this stock in their top 10: 1 1 (0.1%)
13F Filers holding this stock: 128 22 (2.24%)
Aggregate 13F shares on 03/31/2019: 32.722 Million 4.305 Million
Aggregate 13F shares on 12/31/2018: 36.147 Million 3.705 Million
Percent change: -9.48% 16.18%
Funds creating new positions: 25 7
Funds Adding to an existing position: 46 8
Funds closing out their position: 22 4
Funds reducing their position: 31 3
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding FLXN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

8 Thousand total shares from 2 transactions

Open Market Sells (S)

2.2 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

NOVO HOLDINGS A/S

  • 10% Owner
2,674,470 2019-05-13 0

ARKOWITZ DAVID CHIEF FINANCIAL OFFICER

  • Officer
86,924 2019-05-13 7

CLAYMAN MICHAEL D. PRESIDENT AND CEO

  • Officer
  • Director
802,217 2019-05-10 8

LUKATCH HEATH

  • Director
3,481 2019-05-09 0

MILINAZZO ALAN

  • Director
0 2019-04-18 1

MAHATME SANDESH EVP, CFO & CBO

  • Officer
32,437 2019-03-28 1

CANUTE SCOTT A

  • Director
0 2019-03-05 1

BODICK NEIL CHIEF SCIENTIFIC OFFICER

  • Officer
490,465 2019-03-01 4

LEVINE MARK S. GENERAL COUNSEL

  • Officer
45,060 2019-03-01 3

KELLEY SCOTT CHIEF MEDICAL OFFICER

  • Officer
51,271 2019-03-01 3

WENTWORTH KERRY CHIEF REGULATORY OFFICER

  • Officer
56,607 2019-03-01 5

WILLWERTH CHRISTINA CHIEF STRATEGY OFFICER

  • Officer
58,419 2019-03-01 2

COLELLA SAMUEL D

  • Director
158,053 2019-02-12 1

MAHAFFY PATRICK J SEE REMARKS

  • Officer
  • Director
0 2019-02-01 1

DRISCOLL FREDERICK W

  • Director
0 2019-01-02 0

MERRIFIELD C ANN

  • Director
No longer subject to file 2018-08-14 1

STEJBACH MARK

  • Director
0 2018-06-20 1

DENIZ YAMO CHIEF MEDICAL OFFICER

  • Officer
9,000 2017-08-28 0

VERSANT VENTURES III, LLC

VERSANT VENTURE CAPITAL III, L.P.

VERSANT SIDE FUND III, L.P.

VERSANT DEVELOPMENT FUND III, L.P.

ATWOOD BRIAN G

COLELLA SAMUEL D

JAFFE ROSS A MD

LINK WILLIAM J PHD

MILDER DONALD B

ROBERTSON REBECCA B

  • 10% Owner
3,921,092 2016-06-08 0

LUBASH BARBARA N

BOLZON BRADLEY J PHD

WARDEN CHARLES M

PRAEGER ROBIN L.

  • 10% Owner
3,921,092 2016-06-08 0

SOFINNOVA PARTNERS SAS

  • 10% Owner
No longer subject to file 2014-10-29 0

VERSANT VENTURE CAPITAL III, L.P.

VERSANT VENTURES III, LLC

VERSANT SIDE FUND III, L.P.

ATWOOD BRIAN G

COLELLA SAMUEL D

JAFFE ROSS A MD

LINK WILLIAM J PHD

MILDER DONALD B

LUBASH BARBARA N

ROBERTSON REBECCA B

  • Director
  • 10% Owner
2,250 2014-09-10 0

VERSANT VENTURE CAPITAL III, L.P.

BOLZON BRADLEY J PHD

WARDEN CHARLES M

VERSANT DEVELOPMENT FUND III, L.P.

  • Director
  • 10% Owner
2,250 2014-09-10 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

ARKOWITZ DAVID - Officer CHIEF FINANCIAL OFFICER

2019-05-13 P 4,000 $11.99 a 86,924 86,924.00 direct

CLAYMAN MICHAEL D. - Director - Officer PRESIDENT AND CEO

2019-05-10 P 4,012 $12.48 a 74,868 802,217.00 direct

ARKOWITZ DAVID - Officer CHIEF FINANCIAL OFFICER

2019-05-08 S 2,248 $10.06 d 82,924 82,924.00 direct yes
Click here to report any possible errors with this stock listing.

Elevate your investments